Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $403.68 | 28 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valeant Pharmaceuticals North America LLC | $90.64 | 5 | $0 (2017) |
| PFIZER INC. | $58.87 | 4 | $0 (2017) |
| Purdue Pharma L.P. | $53.19 | 4 | $0 (2017) |
| Allergan Inc. | $30.43 | 2 | $0 (2017) |
| Pernix Therapeutics Holdings, Inc. | $25.80 | 2 | $0 (2017) |
| Daiichi Sankyo Inc. | $25.42 | 2 | $0 (2017) |
| Kaleo, Inc. | $24.26 | 2 | $0 (2017) |
| MERZ NORTH AMERICA, INC. | $24.09 | 2 | $0 (2017) |
| Avanir Pharmaceuticals, Inc. | $17.38 | 1 | $0 (2017) |
| Medtronic USA, Inc. | $16.85 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2017 | $403.68 | 28 | Valeant Pharmaceuticals North America LLC ($90.64) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2017 | PFIZER INC. | LYRICA (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 08/17/2017 | Depomed, Inc. | Nucynta (Drug), Gralise | Food and Beverage | In-kind items and services | $11.64 | General |
| Category: Pain | ||||||
| 07/26/2017 | Allergan Inc. | BOTOX NEURO REHAB (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: NEUROSCIENCE | ||||||
| 07/21/2017 | Purdue Pharma L.P. | HYSINGLA ER (Drug) | Food and Beverage | Cash or cash equivalent | $10.78 | General |
| Category: PAIN MANAGEMENT | ||||||
| 05/18/2017 | MERZ NORTH AMERICA, INC. | Xeomin (Biological) | Food and Beverage | Cash or cash equivalent | $11.08 | General |
| Category: Musculoskeletal | ||||||
| 05/17/2017 | PFIZER INC. | LYRICA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 05/10/2017 | Valeant Pharmaceuticals North America LLC | XIFAXAN (Drug), RELISTOR ORAL | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/03/2017 | Purdue Pharma L.P. | BUTRANS (Drug), OXYCONTIN, HYSINGLA ER | Food and Beverage | Cash or cash equivalent | $10.97 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/26/2017 | PFIZER INC. | LYRICA (Drug), FLECTOR PATCH, EMBEDA | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 04/12/2017 | Valeant Pharmaceuticals North America LLC | RELISTOR ORAL (Drug), XIFAXAN, RELISTOR | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/07/2017 | Medtronic USA, Inc. | ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 03/23/2017 | Pernix Therapeutics Holdings, Inc. | ZOHYDRO ER (Drug) | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: PAIN | ||||||
| 03/15/2017 | Valeant Pharmaceuticals North America LLC | RELISTOR ORAL (Drug), XIFAXAN, RELISTOR | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/09/2017 | MERZ NORTH AMERICA, INC. | Xeomin (Biological) | Food and Beverage | Cash or cash equivalent | $13.01 | General |
| Category: Musculoskeletal | ||||||
| 03/02/2017 | Egalet US Inc | OXAYDO (Drug) | Food and Beverage | In-kind items and services | $11.00 | General |
| Category: Pain Medicine | ||||||
| 02/28/2017 | Allergan Inc. | BOTOX NEURO REHAB (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: NEUROSCIENCE | ||||||
| 02/24/2017 | PFIZER INC. | FLECTOR PATCH (Drug), EMBEDA, LYRICA | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 02/17/2017 | Kaleo, Inc. | Evzio (Drug) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: Opioid Antagonist | ||||||
| 02/07/2017 | Valeant Pharmaceuticals North America LLC | RELISTOR ORAL (Drug), XIFAXAN, RELISTOR | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/06/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/24/2017 | Pernix Therapeutics Holdings, Inc. | ZOHYDRO ER (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: PAIN | ||||||
| 01/17/2017 | Valeant Pharmaceuticals North America LLC | RELISTOR (Drug), RELISTOR ORAL | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/17/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/16/2017 | Kaleo, Inc. | Evzio (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Opioid Antagonist | ||||||
| 01/13/2017 | Avanir Pharmaceuticals, Inc. | ONZETRA Xsail (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Migraine | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,383 | 3,680 | $387,116 | $199,073 |
| 2022 | 21 | 1,373 | 3,405 | $332,717 | $168,221 |
| 2021 | 18 | 1,275 | 3,000 | $309,086 | $158,889 |
| 2020 | 17 | 1,134 | 2,349 | $297,337 | $156,153 |
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 106 | 297 | $71,025 | $36,653 | 51.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 210 | 465 | $44,395 | $29,743 | 67.0% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 125 | 148 | $42,940 | $21,536 | 50.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 99 | 202 | $27,340 | $19,497 | 71.3% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 107 | 298 | $36,070 | $17,867 | 49.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 118 | 118 | $21,335 | $12,506 | 58.6% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 36 | 59 | $28,240 | $11,615 | 41.1% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 68 | 122 | $30,528 | $11,332 | 37.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 66 | 67 | $18,090 | $9,422 | 52.1% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 41 | 50 | $24,050 | $7,820 | 32.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 39 | 55 | $9,325 | $4,268 | 45.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $6,175 | $3,747 | 60.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 38 | $6,346 | $3,716 | 58.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 56 | 57 | $7,581 | $3,680 | 48.5% |
| 95908 | Nerve conduction, 3-4 studies | Office | 2023 | 22 | 22 | $4,840 | $1,865 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 24 | $2,832 | $1,700 | 60.0% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 14 | 15 | $2,250 | $1,284 | 57.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 99 | 832 | $2,879 | $698.79 | 24.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 40 | 709 | $709.00 | $69.47 | 9.8% |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | Office | 2023 | 29 | 46 | $138.00 | $51.63 | 37.4% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 22 | 28 | $28.00 | $2.84 | 10.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 334 | 567 | $53,865 | $32,688 | 60.7% |
| 99310 | Follow-up nursing facility visit per day, typically 35 minutes | Facility | 2022 | 70 | 187 | $42,075 | $20,144 | 47.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 140 | 142 | $25,560 | $15,683 | 61.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 110 | 172 | $23,220 | $14,262 | 61.4% |
About Dr. Douglas Boven, M.D
Dr. Douglas Boven, M.D is a Physical Medicine & Rehabilitation healthcare provider based in Royal Oak, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2012. The National Provider Identifier (NPI) number assigned to this provider is 1255696092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Boven, M.D has received a total of $403.68 in payments from pharmaceutical and medical device companies, with $403.68 received in 2017. These payments were reported across 28 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($403.68).
As a Medicare-enrolled provider, Boven has provided services to 5,165 Medicare beneficiaries, totaling 12,434 services with total Medicare billing of $682,336. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Practice Information
- Specialty Physical Medicine & Rehabilitation
- Location Royal Oak, MI
- Active Since 07/09/2012
- Last Updated 07/28/2022
- Taxonomy Code 208100000X
- Entity Type Individual
- NPI Number 1255696092
Products in Payments
- RELISTOR ORAL (Drug) $54.82
- LYRICA (Drug) $46.65
- HYSINGLA ER (Drug) $42.22
- BOTOX NEURO REHAB (Drug) $30.43
- ZOHYDRO ER (Drug) $25.80
- Movantik (Drug) $25.42
- Evzio (Drug) $24.26
- Xeomin (Biological) $24.09
- XIFAXAN (Drug) $18.39
- RELISTOR (Drug) $17.43
- ONZETRA Xsail (Drug) $17.38
- ADAPTIVESTIM (Device) $16.85
- Fentanyl (Drug) $14.11
- FLECTOR PATCH (Drug) $12.22
- Nucynta (Drug) $11.64
- OXAYDO (Drug) $11.00
- BUTRANS (Drug) $10.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physical Medicine & Rehabilitation Doctors in Royal Oak
Dr. Shawn Achtman, D.o, D.O
Physical Medicine & Rehabilitation — Payments: $2,233
Gabrielle Guzzardo, Md, MD
Physical Medicine & Rehabilitation — Payments: $266.62
Lauren Brothers, Do, DO
Physical Medicine & Rehabilitation — Payments: $233.96
Evan Halchishick, Do, DO
Physical Medicine & Rehabilitation — Payments: $118.24
Dr. Lisa Grant, Md, MD
Physical Medicine & Rehabilitation — Payments: $105.37
Dustin Sielski, Md, MD
Physical Medicine & Rehabilitation — Payments: $79.48